Edesa Biotech, Inc. (EDSA)

NASDAQ: EDSA · IEX Real-Time Price · USD
4.35
-0.11 (-2.47%)
At close: Jan 21, 2022 4:00 PM
4.26
-0.09 (-2.07%)
After-hours:Jan 21, 2022 7:17 PM EST
Market Cap58.81M
Revenue (ttm)n/a
Net Income (ttm)-13.34M
Shares Out13.52M
EPS (ttm)-1.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,510
Open4.42
Previous Close4.46
Day's Range4.25 - 4.51
52-Week Range4.15 - 12.00
Beta1.26
AnalystsStrong Buy
Price Target18.00 (+313.8%)
Earnings DateFeb 14, 2022

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermat...

IndustryBiotechnology
Founded2015
Employees16
Stock ExchangeNASDAQ
Ticker SymbolEDSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Edesa Biotech stock is "Strong Buy" and the 12-month stock price forecast is 18.00.

Price Target
$18.00
(313.79% upside)
Analyst Consensus: Strong Buy

News

Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy

Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phas...

1 week ago - Benzinga

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clin...

1 week ago - Accesswire

Edesa Biotech Reports Fiscal Year 2021 Results

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

3 weeks ago - Accesswire

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it h...

1 month ago - Accesswire

Edesa Biotech Extends COVID-19 Clinical Study to Poland

Expansion to European Union country follows favorable Phase 2 results Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:E...

2 months ago - Accesswire

Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related:   Ed...

3 months ago - Benzinga

Why Edesa Biotech Shares Are Trading Higher Today

Edesa Biotech Inc (NASDAQ: EDSA) is trading higher Tuesday after the company announced additional results from the Phase 2 part of the ongoing Phase 2/3 study of EB05 in COVID-19.  Edesa reported that E...

3 months ago - Benzinga

Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for P...

3 months ago - Accesswire

EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Monday

Today, the announcement of positive clinical trial results has sent investors in Edesa Biotech and EDSA stock on a nice ride. The post EDSA Stock: The Covid-19 News Sending Edesa Biotech Soaring on Mond...

4 months ago - InvestorPlace

Why Edesa Biotech Shares Are Soaring Today

Edesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstr...

4 months ago - Benzinga

How To Play Edsa Biotech's Stock After 60% Surge

Edsa Biotech Inc. (NASDAQ:EDSA) shares are trading higher after the company announced Phase 2 Data of its Monoclonal Antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68...

4 months ago - Benzinga

Edesa Biotech Stock Is Rallying After COVID-19 Antibody Data: What You Need To Know

Edesa Biotech Inc (NASDAQ: EDSA) has announced positive results from the Phase 2 part of an ongoing Phase 2/3 study evaluating EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related...

4 months ago - Benzinga

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Data ...

4 months ago - Accesswire

Edesa Biotech to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ON / ACCESSWIRE / September 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr....

4 months ago - Accesswire

Edesa Biotech Provides Update For COVID-19 Antibody Trial

Edesa Biotech Inc (NASDAQ: EDSA) issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients. Edesa reported th...

4 months ago - Benzinga

Edesa Biotech Enrolls More Than 525 COVID-19 Patients Ahead of Schedule

Delta variant contributes to rapid enrollment amid growing scientific rationale for targeting Toll-like Receptor 4 (TLR4) Blinded interim analysis from Phase 2/3 study expected in current quarter TORONT...

4 months ago - Accesswire

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial r...

5 months ago - Accesswire

Edesa Biotech Extends Dermatitis Study to Canada

TORONTO, ON / ACCESSWIRE / July 13, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the com...

6 months ago - Accesswire

Edesa Biotech Team Expands Leadership Team with Key Manufacturing Appointment

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointm...

7 months ago - Accesswire

Edesa Biotech shares jump 14% premarket after early review of COVID treatment finds it should continue trial

Edesa Biotech Inc. shares jumped 14% premarket on Friday, after the Canadian biotech, which is listed on Nasdaq, said an interim review of its one-dose COVID-19 treatment candidate found it should conti...

7 months ago - Market Watch

Edesa Biotech Reports Favorable Review of COVID-19 Study

TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an indep...

7 months ago - Accesswire

Edesa Biotech to Attend BIO Digital 2021

TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the comp...

7 months ago - Accesswire

Edesa Biotech's EB01 Shows Encouraging Interim Results In Dermatitis Trial

Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact Dermati...

7 months ago - Benzinga

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the comp...

7 months ago - Accesswire

Edesa Biotech to Join Panel Discussion at Industry Event

TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to p...

7 months ago - Accesswire